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o We Still Need
rganic Nitrates?*
homas Münzel, MD, FAHA,
hilip Wenzel, MD, Andreas Daiber, PHD
ainz, Germany
rganic nitrates are still quite frequently used for the
reatment of acute and chronic angina, and acute and
hronic congestive heart failure. When given acutely, their
ffectiveness is undisputable; however, their long-term effi-
acy is substantially limited due to the development of
olerance (1) and the induction of endothelial dysfunction (2),
parameter that has prognostic significance in patients with
oronary artery disease, hypertension, and heart failure (3).
In this issue of the Journal, Thomas et al. (4) showed that
herapy with isosorbide mononitrate (ISMN) leads to en-
othelial dysfunction, increases oxidative stress, and that
his condition is improved by acute administration of
itamin C. One might conclude that this was predictable
ince this has been shown for nitroglycerin (GTN) and all
itrates are the same. In fact, all nitrates are not all the same
nd, therefore, the paper by Thomas et al. (4) has substan-
ial importance.
See page 1289
Organic nitrates need to undergo intracellular metabo-
ism in order to produce vasodilatation, a process often
eferred to as bioactivation. During the past 3 to 4 years,
ubstantial insight into this bioactivation process has been
ained and we have also learned a substantial amount about
he mechanisms underlying nitrate tolerance. In the early
990s, we found that treatment of animals with GTN
atches caused tolerance and endothelial dysfunction (the
henomenon of cross-tolerance) and that this phenomenon
as linked to the capacity of GTN to stimulate the production
f reactive oxygen species (ROS) within the vascular tissue (5).
s potential superoxide sources, the vascular nicotinamide
denine dinucleotide phosphate (NADPH) oxidases (6) and
n uncoupled nitric oxide (NO) synthase (7) were identified.
t that time we believed that this concept could be extended
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.i
From the II Medizinische Klinik für Kardiologie und Angiologie, Johannes
utenberg Universität Mainz, Mainz, Germany.o all other nitrates. There was no reason to believe that
ifferent organic nitrates such as GTN, pentaerythrityl
etranitrate (PETN), isosorbide dinitrate (ISDN), and
SMN were bioactivated by different enzymes. This view,
owever, has changed substantially within the last couple of
ears.
A breakthrough in this field came with the discovery that
he mitochondrial aldehyde dehydrogenase (ALDH-2) was
nvolved in this bioactivation process and could metabolize
TN leading to NO or a related compound (Fig. 1) (8). In
ooperation with Chen et al. (8), Sydow et al. (9) demonstrated
hat oxidative stress within the mitochondria caused inactiva-
ion of ALDH-2, and that this is a key mechanism underlying
mpaired GTN biotransformation during prolonged treatment
f cultured cells, animals (9), and patients (U. Hink, unpub-
ished observation, 2006) with GTN. This observation linked
he oxidative stress concept of tolerance with the impaired
iotransformation concept of nitrate tolerance.
Interestingly, ALDH-2 is only responsible for bioactiva-
ion of nitrates with the highest vasodilator potency such as
TN and PETN as well as for the PETN-derived trinitrate
ETriN; ALDH-2 does not seem to be involved in bioac-
ivation of dinitrates and mononitrates (Fig. 1). Recent
tudies by our group suggest that the propensity for
LDH-2 to bioactivate an organic nitrate is related to the
umber of nitrate moieties within the compound (10).
It is also important to note that, in ALDH-2 knockout
nimals, the shift of the GTN dose-response curve is
dentical as compared with the shift observed in vessels from
ild-type animals treated with an ALDH-2 inhibitor.
mportantly, inhibition of this enzyme by knockout or
nhibitors, however, does not completely prevent the GTN
nd PETN vasodilating capacity suggesting that other
nzymes are almost certainly involved in GTN bioactiva-
ion. A likely candidate is 1 or more cytochrome P450
ubtypes in the endoplasmic reticulum. These alternate
nzymes seem to be involved in the metabolism of higher
oncentrations—a so-called low-affinity pathway for GTN
iotransformation (11). Thus, it is likely that GTN and PETN
ndergo biotransformation via completely different enzymes
han ISDN and ISMN (Fig. 1). Of note, incubation of isolated
itochondria with GTN markedly increases mitochondrial
uperoxide production while incubation with ISMN does not
10). This observation is important since both tolerance and
ross-tolerance to endothelium-dependent vasodilators have
een recently linked to the capacity of GTN to stimulate
itochondrial superoxide formation (12).
Based on this background, the study by Thomas et al. (4)
hould be of substantial interest to cardiologists because
ononitrates are still frequently used worldwide to treat
atients with stable angina symptoms. These investigators
reated healthy volunteers with isosorbide-5-mononitrate
IS-5-MN) once daily or with a placebo. One week of
SMN treatment caused a marked blunting of the increase
n forearm blood flow in response to acetylcholine. In
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March 27, 2007:1296–8 Editorial Commentddition, the vasoconstriction caused by the NO synthase
nhibitor NG-monomethyl-L-arginine was substantial re-
uced. These 2 findings suggested that both baseline and
timulated bioactivity of endogenous endothelial NO was
ltered by ISMN therapy. The exciting point was that
dministration of vitamin C completely normalized vasodila-
ion induced by acetylcholine demonstrating a crucial role of
uperoxide anions or other related ROS in this vascular
bnormality caused by ISMN therapy. Taken together, this is
he first study to show that mononitrates cause endothelial
ysfunction and the first study to show that treatment with
ononitrates stimulates oxidative stress within vascular tissue.
What is the source of superoxide in the case of ISMN-
nduced tolerance? Surprisingly, there have been no studies
f experimental animals using mononitrates to address this
uestion. It is unlikely the mitochondria because, as men-
ioned above, ISMN is not bioactivated by the mitochon-
ria. Likely candidates for superoxide-producing enzymes
ontributing to endothelial dysfunction in response to
SMN include xanthine oxidase, the vascular NADPH
xidase, and also an uncoupled NO synthase.
Thus, the results of Thomas et al. (4) will stimulate
dditional research on this topic, and it is likely that the
nzyme involved in mononitrate bioactivation, still a mys-
ery, will be identified.
The study by Thomas et al. (4) might be criticized
ecause it was performed in control subjects rather than
atients, which may make it difficult to translate these data
Figure 1 The Scheme Depicts Proposed Pathways of Organic N
The left part characterizes the bioactivation of high potency nitrates such as nitrog
by mitochondrial aldehyde dehydrogenase (ALDH-2), when employed at clinically re
nitrite and the denitrated metabolite (1,2-glyceryl dinitrate [GDN], PETriN or its dini
respiratory chain (cytochrome oxidase [cyt ox]) or acidic disproportionation in the i
which is able to activate soluble guanylyl cyclase. The resulting increase in cyclic g
turn causes vasodilatation via several mechanisms. The right portion depicts the
5-mononitrate (ISMN) but also GDN, PEDN, and their respective mononitrates, glyc
plasmic reticulum (ER) directly yielding. The latter mechanism also accounts for th
with permission from Munzel et al. (11). sGC  soluble guanylate cyclase.nto the clinical situation. In our opinion, this is not a broblem at all. Usually, in patients with coronary artery
isease, vascular oxidative stress already exists. Thus, treat-
ng these patients with NO (via mononitrates) very likely
ill lead to formation of the NO/superoxide reaction
roduct peroxynitrite (ONOO) (13), which in turn can
mpair endothelial function by uncoupling endothelial NO
ynthase (7), by causing tyrosine nitration of prostacyclin
ynthase leading to a reduction of PGI2 formation (13) and
y inhibiting the NO signaling within smooth muscle cells.
hus, the demonstration that endothelial dysfunction can
e induced in control subjects, where NO generally exceeds
uperoxide production, illustrates to us how potently mono-
itrates diminish endothelial function.
The results of this study might also explain the recent
eta-analysis showing how treatment of post-infarction
atients with mono- and dinitrates actually worsened their
utcome (14).
These results also again challenge the concept that
atients with coronary artery disease and stable angina
hould routinely be treated with nitrates to improve symp-
omatology and raise the question of whether organic
itrates should be used at all. The guidelines of the
merican Heart Association/American College of Cardiol-
gy for treatment of stable coronary artery disease have
lready taken this question into account and recommended
hort-acting nitrates or a calcium antagonist such as amlo-
ipine rather than a mono- or dinitrate, when patients
emain symptomatic even after treatment with a beta-
Bioactivation in Vascular Cells
(GTN), pentaerythrityl tetranitrate (PETN), and pentaerythrityl trinitrate (PETriN)
concentrations (1 M). The reductase activity converts the organic nitrates to
EDN). Nitrite in turn requires further bioactivation by either reduction by the
embrane space, finally yielding nitric oxide (NO) or a related species (NOx),
ine monophosphate (cGMP) will activate the cGMP-dependent kinase I, which in
vation of low-potency nitrates such as isosorbide dinitrate (ISDN) and isosorbide-
MN) and pentaerythytyl mononitrate (PEMN), by P450 enzyme(s) in the endo-
-potency nitrates, when employed at high concentrations (1 M). Reprinteditrate
lycerin
levant
trate P
nner m
uanos
bioacti
eryl (G
e highlocker, aspirin, and a statin (15).
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